Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease
In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely consistent with the overall trend in Alzheimer's drug evaluations that target amyloid beta - the protein that forms deposits in the brain tissue of patients with the disease - resulting in the abandonment of dozens of candidates.
The GRADUATE I and II studies, which included 1,965 subjects with mild cognitive impairment (MCI) due to Alzheimer's and mild A...
